Analysts Set Expectations for Immunic FY2025 Earnings

Immunic, Inc. (NASDAQ:IMUX) – Stock analysts at Brookline Capital Management issued their FY2025 earnings per share estimates for Immunic in a research report issued to clients and investors on Tuesday, February 3rd. Brookline Capital Management analyst F. Ahmed anticipates that the company will post earnings per share of ($0.65) for the year. Brookline Capital Management currently has a “Strong-Buy” rating on the stock. The consensus estimate for Immunic’s current full-year earnings is ($0.94) per share. Brookline Capital Management also issued estimates for Immunic’s Q4 2025 earnings at ($0.12) EPS, Q1 2026 earnings at ($0.13) EPS, Q2 2026 earnings at ($0.12) EPS, Q3 2026 earnings at ($0.11) EPS, Q4 2026 earnings at ($0.10) EPS and FY2026 earnings at ($0.46) EPS.

Immunic (NASDAQ:IMUX) last posted its quarterly earnings results on Thursday, November 13th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.18) by $0.05.

Several other equities analysts have also recently weighed in on IMUX. LADENBURG THALM/SH SH raised shares of Immunic to a “strong-buy” rating in a research note on Thursday, October 16th. Weiss Ratings reissued a “sell (e+)” rating on shares of Immunic in a report on Monday, December 29th. Roth Mkm began coverage on Immunic in a report on Friday, November 7th. They issued a “buy” rating and a $3.00 target price on the stock. HC Wainwright decreased their target price on Immunic from $10.00 to $8.00 and set a “buy” rating on the stock in a research report on Friday, November 14th. Finally, Chardan Capital raised Immunic to a “strong-buy” rating in a research note on Wednesday, November 19th. Three research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Immunic presently has an average rating of “Buy” and an average price target of $7.40.

Immunic Price Performance

Immunic stock opened at $0.59 on Friday. Immunic has a 1 year low of $0.51 and a 1 year high of $1.39. The firm’s 50 day moving average price is $0.63 and its 200-day moving average price is $0.77. The stock has a market cap of $70.85 million, a P/E ratio of -0.71 and a beta of 1.58.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Qube Research & Technologies Ltd bought a new stake in Immunic during the third quarter worth approximately $29,000. Millennium Management LLC boosted its holdings in shares of Immunic by 414.5% in the 3rd quarter. Millennium Management LLC now owns 530,470 shares of the company’s stock worth $468,000 after purchasing an additional 427,361 shares during the period. Focus Partners Wealth increased its position in shares of Immunic by 1.5% during the 3rd quarter. Focus Partners Wealth now owns 2,581,587 shares of the company’s stock valued at $2,276,000 after purchasing an additional 39,063 shares during the last quarter. Virtu Financial LLC purchased a new stake in Immunic during the 3rd quarter valued at $99,000. Finally, Two Sigma Investments LP bought a new stake in Immunic in the third quarter worth $52,000. Hedge funds and other institutional investors own 51.82% of the company’s stock.

Immunic Company Profile

Immunic, Inc is a clinical-stage biopharmaceutical company focused on developing novel oral therapies to treat chronic inflammatory and autoimmune diseases as well as certain cancers. The company’s research strategy centers on small-molecule immunology, aiming to offer targeted treatments with improved safety and tolerability profiles. By modulating key signaling pathways within the immune system, Immunic seeks to address underlying disease mechanisms and achieve durable therapeutic benefits for patients.

Immunic’s lead product candidate, vidofludimus calcium (IMU-838), is an oral selective dihydroorotate dehydrogenase (DHODH) inhibitor in Phase 2 clinical development for conditions including ulcerative colitis, Crohn’s disease and relapsing multiple sclerosis.